Evidence map›Paper›PMID 26640777›Full record

ArticleFrontiers in oncology2015

Paving the Road for Modern Particle Therapy - What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?

Hanno M Specht, Teresa Neff, Waltraud Reuschel, Franz M Wagner, Severin Kampfer, Jan J Wilkens, Winfried Petry, Stephanie E Combs

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Particle therapy in Europe.Molecular oncology · 2020
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hanno M SpechtDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München , Munich , Germany.
Teresa NeffDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München , Munich , Germany.
Waltraud ReuschelDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München , Munich , Germany.
Franz M WagnerForschungs-Neutronenquelle Heinz Maier-Leibnitz II (FRM II), Technische Universität München , Garching , Germany.
Severin KampferDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München , Munich , Germany.
Jan J WilkensDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München , Munich , Germany ; Institute of Innovative Radiotherapy (iRT), Department of Radiation Science, Helmholtz Zentrum München , Oberschleißheim , Germany.
Winfried PetryForschungs-Neutronenquelle Heinz Maier-Leibnitz II (FRM II), Technische Universität München , Garching , Germany.
Stephanie E CombsDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München , Munich , Germany ; Institute of Innovative Radiotherapy (iRT), Department of Radiation Science, Helmholtz Zentrum München , Oberschleißheim , Germany.
Technical University of Munich · DEKlinikum rechts der Isar · DEInstitute of Bioinformatics and Systems Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While neutron therapy was a highly topical subject in the 70s and 80s, today there are only a few remaining facilities offering fast neutron therapy (FNT). Nevertheless, up to today more than 30,000 patients were treated with neutron therapy. For some indications like salivary gland tumors and malignant melanoma, there is clinical evidence that the addition of FNT leads to superior local control compared to photon treatment alone. FNT was available in Munich from 1985 until 2000 at the Reactor Neutron Therapy (RENT) facility. Patient treatment continued at the new research reactor FRM II in 2007 under improved treatment conditions, and today it can still be offered to selected patients as an individual treatment option. As there is a growing interest in high-linear energy transfer (LET) therapy with new hadron therapy centers emerging around the globe, the clinical data generated by neutron therapy might help to develop biologically driven treatment planning algorithms. Also FNT might experience its resurgence as a combinational partner of modern immunotherapies.

Indexed as

adenoidcystic carcinomafast neutronsfast neutron therapyhigh-LET radiationRBEreactor neutrons

Identifiers

PMID26640777
PMCPMC4661227
OpenAlexW2178561860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.